Dr. Paika Podcast

#GLP1 #Microdosing #Zepbound #Ozempic #WeightLossMaintenance

Microdosing Zepbound & Ozempic: How Low Can You Go and Still Keep the Weight Off?

You hit your goal weight. Now the question is: do you have to stay on this dose forever? More and more people are cutting their GLP-1 dose to a fraction or stretching their shots to every 10 to 14 days, hoping to save money, cut side effects, and keep the weight off.

I'm Dr. Mohammed Paika, a board-certified internal medicine and obesity medicine physician and practicing hospitalist. In this video I break down what the research actually shows about lower-dose GLP-1 maintenance, and what it doesn't show yet.


🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

TIMESTAMPS
0:00 Do I have to stay on this dose forever?
1:24 The rebound: what happens when you stop
2:49 Why microdosing is trending now
4:01 What is microdosing? The minimal effective dose
5:02 Two approaches: dose reduction vs. interval spacing
6:01 What happens at lower doses
7:35 Muscle preservation
9:14 What the evidence says: SURMOUNT-MAINTAIN
12:03 Why the weight comes back: the set point
13:35 Why people want a lower dose: cost, supply, side effects
14:16 The 4 risks of going too low
17:06 My step-down framework
18:38 How low can you go? The bottom line

REFERENCES
1. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564.
2. Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA. 2024;331(1):38-48.
3. SURMOUNT-4 post hoc analysis of weight regain. JAMA Intern Med. 2025.
4. Evidation. Real-world GLP-1 dosing behaviors (preliminary survey). December 2025.
5. Bickel CS, Cross JM, Bamman MM. Exercise dosing to retain resistance training adaptations in young and older adults. Med Sci Sports Exerc. 2011;43(7):1177-1187.
6. Wegovy (semaglutide), Ozempic (semaglutide) and Zepbound (tirzepatide) US prescribing information.
7. Hackensack Meridian Health. Is microdosing GLP-1s safe? May 2026.
8. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409-1439.
9. Nauck MA, et al. Rapid tachyphylaxis of the GLP-1-induced deceleration of gastric emptying in humans. Diabetes. 2011;60(5):1561-1565.
10. O'Neil PM, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss (phase 2). Lancet. 2018;392:637-649.
11. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
12. Wilding JPH, et al. STEP 1 body composition (DXA) substudy. J Endocr Soc. 2021;5(Suppl 1):A16-A17.
13. Look M, et al. SURMOUNT-1 body composition (DXA) substudy. Diabetes Obes Metab. 2025.
14. SURMOUNT-MAINTAIN. Tirzepatide maximum dose vs. 5 mg vs. placebo for weight maintenance. Lancet. May 2026.
15. Gudbergsen H, et al. Semaglutide with a digital weight-management program in Denmark (Embla), lowest effective dose. 2025.
16. Embla semaglutide tapering study. European Congress on Obesity. 2024.
17. ClinicalTrials.gov NCT07783854. Randomized dose-tapering regimen of semaglutide for weight-loss maintenance.
18. Eli Lilly. ATTAIN-MAINTAIN topline results (orforglipron). December 2025.
19. Sumithran P, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365:1597-1604.
20. Fothergill E, et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity. 2016;24(8):1612-1619.
21. Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression. 2025.
22. Eli Lilly. Zepbound KwikPen instructions for use and FAQ (priming). 2026.
23. US FDA. Dosing errors with compounded semaglutide. July 26, 2024.


⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

What is Dr. Paika Podcast?

Welcome to the Dr. Paika Podcast — where medicine, fitness, and humanity come together.

Hosted by Dr. Mohammed K. Paika, M.D., double board-certified in obesity & internal medicine with close to 20 years of hospital experience, this show dives deep into the science of health, obesity, longevity, and mindset — but with compassion, not complexity.

From hospital medicine to the gym floor, from patient care to personal growth — every episode blends real clinical insight with practical, inspiring stories that help you live better and think deeper.

💡 Topics include:

Obesity & metabolic health

Longevity & fitness

Nutrition & preventive medicine

Doctor insights from close to 20 years in hospitals across the US!

Mindset, mental health, and motivation

🎧 Subscribe for weekly conversations that are honest, empowering, and rooted in science — all from a doctor who believes medicine should heal the mind and body.